Best practices for machine learning in antibody discovery and development.

Autor: Wossnig L; LabGenius Ltd, The Biscuit Factory, 100 Drummond Road, London SE16 4DG, UK; Department of Computer Science, University College London, 66-72 Gower St, London WC1E 6EA, UK. Electronic address: leonard.wossnig@labgeni.us., Furtmann N; R&D Large Molecules Research Platform, Sanofi Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Buchanan A; Biologics Engineering, R&D, AstraZeneca, Cambridge CB2 0AA, UK., Kumar S; Computational Protein Design and Modeling Group, Computational Science, Moderna Therapeutics, 200 Technology Square, Cambridge, MA 02139, USA., Greiff V; Department of Immunology and Oslo University Hospital, University of Oslo, Oslo, Norway.

Publikováno v: Drug discovery today [Drug Discov Today] 2024 Jul; Vol. 29 (7), pp. 104025. Date of Electronic Publication: 2024 May 17.

Substrate specificity of human matriptase-2

Autor: Wysocka, M., Gruba, N., Miecznikowska, A., Popow-Stellmaszyk, J., Gütschow, M., Stirnberg, M., Furtmann, N., Bajorath, J., Lesner, A., Rolka, K.

Publikováno v: In Biochimie February 2014 97:121-127

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections.

Autor: Promsote W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Xu L; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA.; ModeX Therapeutics Inc., 22 Strathmore Road, Natick, MA, 01760, USA., Hataye J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Fabozzi G; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., March K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Almasri CG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., DeMouth ME; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Lovelace SE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Talana CA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Doria-Rose NA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., McKee K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hait SH; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Casazza JP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Ambrozak D; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Beninga J; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Rao E; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Furtmann N; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Birkenfeld J; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA.; Perspix Biotech GmbH, FiZ Frankfurt Innovation Center Biotechnology, Altenhoeferallee 3, 60438, Frankfurt, Germany., McCarthy E; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Todd JP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Petrovas C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital (chuv) and University of Lausanne, Lausanne, Switzerland., Connors M; NIAID, NIH, Bethesda, MD, 20892, USA., Hebert AT; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Beck J; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Shen J; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Zhang B; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Levit M; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA., Wei RR; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA.; ModeX Therapeutics Inc., 22 Strathmore Road, Natick, MA, 01760, USA., Yang ZY; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA.; ModeX Therapeutics Inc., 22 Strathmore Road, Natick, MA, 01760, USA., Pegu A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.; ModeX Therapeutics Inc., 22 Strathmore Road, Natick, MA, 01760, USA., Nabel GJ; Sanofi, 640 Memorial Dr., Cambridge, MA, 02139, USA. gary.nabel@modextx.com.; ModeX Therapeutics Inc., 22 Strathmore Road, Natick, MA, 01760, USA. gary.nabel@modextx.com., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. rkoup@nih.gov.

Publikováno v: Nature communications [Nat Commun] 2023 Jun 22; Vol. 14 (1), pp. 3719. Date of Electronic Publication: 2023 Jun 22.

An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.

Autor: Furtmann N; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Schneider M; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Spindler N; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Steinmann B; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Li Z; R&D Integrated Drug Discovery Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Focken I; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Meyer J; Digital R&D, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Dimova D; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Kroll K; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Leuschner WD; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Debeaumont A; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Mathieu M; R&D Integrated Drug Discovery France, Sanofi, Vitry Sur Seine Cedex, France., Lange C; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Dittrich W; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Kruip J; IA Specialty Care Digital Innovation Biologics, Sanofi-Aventis Deutschland GmbH, Frankfurt Am Main, Germany., Schmidt T; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany., Birkenfeld J; R&D Large Molecules Research Platform Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt Am Main, Germany.

Publikováno v: MAbs [MAbs] 2021 Jan-Dec; Vol. 13 (1), pp. 1955433.

Assessing the Potential of 1,2,3-Triazole-Dihydropyrimidinone Hybrids Against Cholinesterases: In Silico, In Vitro, and In Vivo Studies.

Autor: Gastalho, Carlos M.^1,2,3 (AUTHOR) cgastalho@gmail.com, Sena, Ana M.⁴ (AUTHOR) ana.m.sena98@gmail.com, López, Óscar⁵ (AUTHOR) osc-lopez@us.es, Fernández-Bolaños, José G.⁵ (AUTHOR) bolanos@us.es, García-Sosa, Alfonso T.⁶ (AUTHOR) alfonsog@ut.ee, Pereira, Florbela⁷ (AUTHOR) florbela.pereira@fct.unl.pt, Antunes, Célia M.^2,3,8 (AUTHOR) acrc@uevora.pt, Costa, Ana R.^2,3,8 (AUTHOR), Burke, Anthony J.^1,9,10,11 (AUTHOR) ajburke@ff.uc.pt, Carreiro, Elisabete P.¹ (AUTHOR) betepc@uevora.pt

Publikováno v: International Journal of Molecular Sciences. Oct2024, Vol. 25 Issue 20, p11153. 20p.